Background: Sirukumab (SIR), a human monoclonal antibody that selectively binds the IL-6 cytokine, is in development for the treatment of rheumatoid arthritis (RA). Efficacy of SIR was shown in several phase 3 trials in RA patients (pts; SIRROUND program). Objectives: To analyze safety data from completed/ongoing studies in the SIRROUND program. Methods: Safety comparisons included SIR 50mg q4w and 100mg q2w doses vs placebo (pbo) in the pbo-controlled period (Wk 0-18) of 2 phase 3 studies. A long-term comparison of the safety of SIR 50mg q4w and 100mg q2w for the entire program was also performed. Results: In phase 3 studies, 2926 pts received SIR for up to 3.4y (median duration, 1.46y). During Wk 0-18, there were more adverse events (AEs), AEs leading to discontinuation, and serious AEs (SAEs) with SIR vs pbo, with cumulative rates of SAEs remaining constant over time (Table) . In general, no dose effect with SIR was observed in the 18-wk or long-term analysis. Mortality rates were similar across treatment groups through 18 wks and remained stable in long-term analysis. Serious infections were more frequent in SIR-treated pts vs pbo during Wk 0-18, with similar rates through long-term analysis. Rates of
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